Boston Scientific opened higher at $42.95, compared with its previous close of $42.69. In the last trading session, the stock traded between $42.26 and $43.29. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Boston Scientific is now worth
$ 99.36
resulting in a loss of
$ 0.64 (0.64%)
Note: Past profits do not guarantee future returns.
Rating from 21 Analysts
Today's Change
+$0.17 (+0.39%)
Day High
$43.29
Day Low
$42.26
Day Open
$42.95
Prev Close
$42.69
Volume
82,25,413
1W Return
-6.87%
1M Return
-2.20%
3M Return
-7.11%
6M Return
-25.01%
1Y Return
-57.27%
Market Cap ($ Mn)
62,107
PE Ratio
18.96
PB Ratio
2.72
PEG Ratio
0.41
ROE
12.68%
ROCE
10.29%
EPS (TTM)
$0.63
1 Week
-6.87%
1 Month
-2.20%
3 Months
-7.11%
6 Months
-25.01%
9 Months
-53.58%
Truist maintains Buy on Boston Scientific, cuts price target to $51
Truist Securities analyst Richard Newitter maintains a Buy rating on Boston Scientific. The price target is lowered from $57 to $51, a reduction of $6 per share. The rating remains unchanged despite the downward revision in the target price.
15 days agoBoston Scientific appoints Joseph M. Fitzgerald as COO effective Jan 2027
Joseph M. Fitzgerald appointed EVP and COO effective January 1, 2027. Currently serves as group president, Cardiovascular division. Led portfolio strengthening via organic innovation and strategic investments.
23 days agoFDA classifies Boston Scientific catheter recall as Class I
FDA classifies recall of Imager II Angiographic Catheters as Class I. Defect involves inadequate stabilizing agents causing tip detachment. Two injuries reported as of July 16; no deaths recorded. Boston Scientific permanently discontinuing the affected product line.
1mo agoBoston Scientific re-evaluates 2027 framework after cyberattack
Boston Scientific re-evaluating 2027 financial framework due to cyber incident. Company executing significant restructuring plan for financial benefit. Preview of new outlook expected in October. Firm expects to miss Q3 and FY26 guidance issued in July. Shares fell 5.31% to $45.26 on Tuesday.
1mo agoBoston Scientific recalls spinal cord stimulator leads over fracture risk
Boston Scientific issues Class I recall for Infinion CX Spinal Cord Stimulator leads. FDA cites fracture risk and severe patient harm; 1,081 serious injuries reported. Recall applies only to un-implanted inventory; implanted patients need no extra care. No deaths reported despite mechanical stress causing lead fractures or high impedance. BSX stock rose 1.77% to $47.78 following the regulatory advisory release.
1mo agoWisner Baum Named Co-Lead Counsel in Boston Scientific Spinal Cord Stimulator MDL
Behram V. Parekh appointed Co-Lead Counsel in Boston Scientific spinal cord stimulator MDL No. 3181. Hannah Quicksell named to Leadership Development Committee for coordinated discovery phase. Plaintiffs allege device failures and insufficient clinical trials for post-approval modifications. Consolidation of cases against Abbott and Nevro scheduled for September 24 hearing consideration.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 | |
| $32.00 | -1.14% | $28,075.23M | 89.05 |
An investment of $100 made 5 years ago in Boston Scientific is now worth
$ 99.36
resulting in a loss of
$ 0.64 (0.64%)
Note: Past profits do not guarantee future returns.
